Report initial safety and efficacy data from first 40 patients in Module A
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 25 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- September 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initial safety and efficacy data from among the first 40 patients enrolled in Module A, which is evaluating margetuximab in combination with retifanlimab (an anti-PD-1 therapy), are expected in the first half of 2021.”
What we found
Evidence strength A What the grades mean
The company's July 2021 8-K moved the Module A data report to ESMO in September 2021, and the 2022 10-K says the data were presented in September 2021, after the June 2021 deadline.
-
A Macrogenics Inc. 8-K filed 2021-07-29
“The Company plans to report interim safety and efficacy data on these patients at ESMO in September 2021.” ✓ confirmed on the page
-
A Macrogenics Inc. 10-K filed 2022-02-24
“In September 2021, we presented data from Part 1, Module A of the Phase 2/3 MAHOGANY clinical trial of margetuximab at the 2021 ESMO Virtual Conference.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- Initial safety and efficacy data from Module A, MAHOGANY study
- Target
- 40 patients
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Macrogenics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-MGNX-024450 · Corrections policy